Investor Relations

INVESTORS & MEDIA

INVESTORS
& MEDIA

We are a leading science and technology company that delivers life-transforming medicines for serious diseases.

Founded by physician-scientists nearly 30 years ago, our science-driven approach has resulted in six FDA-approved medicines and numerous product candidates in a range of diseases, including cancer, asthma, pain and infectious diseases.

In addition to our medicines, our innovations include the VelociSuite® technologies, world-class manufacturing operations, one of the largest human sequencing efforts in the world and rapid response technologies being used for global good.

 

NASDAQ REGN

$438.17 0.00 (0.00)%

High N/A Low N/A Volume N/A Market Cap 45.74B
09/20/17 4:00 PM ET | Minimum 20 minutes delay.

Stock information provided by eSignal.

Financial information

NEWSROOM

  • Sep 16

    Regeneron and Sanofi Announce Positive Study Results for DUPIXENT® (dupilumab) in Patients With Moderate-to-Severe Atopic Dermatitis

    Read on
  • Sep 11

    Regeneron and Sanofi Announce Positive Dupilumab Topline Results from Phase 3 Trial in Uncontrolled Persistent Asthma

    Read on

EVENTS

  • EADV 2017
    Sep 16, 2017

  • Bank of America Merrill Lynch Global Healthcare Conference
    Sep 13, 2017 | 5:40 AM ET

Events & Presentations

NASDAQ REGN

$438.17 0.00 (0.00)%

High N/A Low N/A Volume N/A Market Cap 45.74B
09/20/17 4:00 PM ET | Minimum 20 minutes delay.

Stock information provided by eSignal.

Stock information

Financial information